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Background: Despite the substantial global burden of disease, rheumatic heart disease research receives little
funding globally.
Methods: Using data from the Global Burden of Disease Study and funding from the G-FINDER database, we
propose a novel logarithmic disability neglect index (DNI) to describe disease burden using disability-adjusted
life years relative to funding for 16 major tropical diseases.
Results: Across a range of diseases, rheumatic heart disease received the least funding relative to disease bur-
den (DNI=3.83). Other diseases facing similar underfunding include cysticercosis (DNI=2.71) and soil-
transmitted helminths (DNI=2.41).
Conclusions: Rheumatic heart disease remains severely underfunded relative to disease burden.
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Background
Rheumatic heart disease (RHD) is a long-term consequence of
an aberrant immune response to the bacterium Streptococcus
pyogenes (Group A streptococcus [GAS]) that leads to scarring
and dysfunction of the heart valves.1 The disease is thought to
develop years after the onset of an acute immunological
response to GAS pharyngitis, or GAS impetigo in the tropics.2
RHD most commonly presents in adolescence or early adult-
hood with palpitations and shortness of breath. In addition to
being a major cause of heart failure and stroke, RHD is highly
likely to be the leading cause of cardiac death in children and
young adults in developing countries.3,4
RHD is thought to affect at least 33 million people globally,
causing an estimated 300 000 deaths each year,5 yet a poor
understanding of disease pathogenesis has limited the oppor-
tunities for innovations in disease control.6 Despite the huge
burden of disability, RHD continues to receive relatively little
attention from researchers and the global health community
alike, and attracts little research funding relative to its global
burden, totalling approximately US$1.2 million in research fund-
ing in 2017.7 Indeed, it is often said that relative to its global
burden, RHD receives limited research funding, but the degree
to which it is underfunded has not previously been quantiﬁed.
We therefore set out to explore the extent to which the burden
of a tropical disease relates to the quantity of research funding
the disease attracts. We compared disease-speciﬁc funding and
disability-adjusted life years (DALYs) for a range of infectious dis-
eases of global signiﬁcance. Here we propose a simple and
objective method for comparing relative funding neglect
between diseases to identify diseases such as RHD that suffer
from severe underfunding relative to their overall global burden.
Methods
Using data from the Global Burden of Disease, Injuries, and Risk
Factors Study 2017,7 we obtained disease-speciﬁc burden esti-
mated by DALYs, with analysis restricted to infectious diseases
with >100 000 attributable DALYs per year.
Disease-speciﬁc research and development funding was
obtained from the freely available G-FINDER public search tool.8
Five-year average funding estimates over the period 2013–2017
were used to limit bias in cases where signiﬁcant grants had
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been made in a given year, with all estimates adjusted for inﬂa-
tion to 2017 US dollars. Only disease-speciﬁc funding was con-
sidered, so it is possible that the true total disease funding
attributed to some diseases is higher than reported since indi-
vidual grants may cover a range of diseases in some instances.
We explored variations of funding mapped to disease burden
using visual plots and created a logarithmic disability neglect
index (DNI), deﬁned as the negative common logarithm (i.e.
−log10) of DALYs (in thousands) divided by funding in US dollars
(in millions) for each disease, to compare the extent to which
disease funding varies by the associated global disability
burden.
Results
We identiﬁed paired funding and disability and/or mortality data
for 16 tropical infectious diseases for which data were available
(Table 1, Figure 1). The total funding attributed to these diseases
from 2013 to 2017 was US$13.1 billion (mean US$2.6 billion per
year). These diseases contributed >180 million DALYs and 3.3
million deaths in 2017. Human immunodeﬁciency virus (HIV)/
acquired immune deﬁciency syndrome (AIDS), tuberculosis (TB)
and malaria were associated with 2.7 million deaths and 144
million DALYs in 2017. After these, the next two largest contribu-
tions to mortality and disability were RHD (285 000 deaths, 9.4
million DALYs) and typhoid/paratyphoid fever (136 000 deaths,
9.8 million DALYs).
Figure 2 shows the DNI for all included diseases. The mean of
all estimates was 2.01 (US$9.77 per DALY) and the mean for
HIV/AIDS, TB and malaria combined was 1.82 (US$15.02 per
DALY). The highest values (lowest number of US$s per DALY)
were RHD (3.83 [US$0.15 per DALY]), cysticercosis (2.71 [US
$1.84 per DALY]) and soil-transmitted helminths (2.41 [US$3.89
per DALY]).
Discussion
Despite growing recognition that RHD is a global public health
concern,5,9 much remains to be done and substantial ﬁnancial
investment is needed, particularly to develop and trial a
safe vaccine against the causative GAS. It therefore remains
necessary to demonstrate to funders that the global burden of
this disease outstrips research and development spending.
Consequently we have attempted to quantify that discrepancy
and make objective comparisons with other important infec-
tious diseases of global concern.
The DNI is higher for RHD than any other disease we
assessed and is 2 points higher than HIV/AIDS, TB and malaria.
To put this in context, on average, each dollar of RHD research
funding has to contend with 100 times the number of DALYs of
Table 1. Research and development (R&D) funding and associated DALYs in 2017 for RHD and 15 major tropical infectious diseases (Global
Burden of Disease Study 2017, G-FINDER public research tool 2017) with associated DNI
Diseasea Yearly R&D spending (million US$)b DALYsd (1000s) R&D (US$ per DALY) DNIe
2013 2014 2015 2016 2017 5-y averagec
RHD 0.9 1.3 2.3 1.3 1.2 1.39 9393 0.15 3.83
Cysticercosis 1.79 2.39 2.69 3.61 5.37 3.17 1608 1.97 2.71
Soil-transmitted helminths 8 7.7 8.3 7 6.3 7.47 1919 3.89 2.41
Typhoid and paratyphoid fever 47.8 47.9 55 71.4 63.7 57.17 9801 5.83 2.23
Trachoma 2.2 1.35 1.15 2.18 2.67 1.91 302.9 6.31 2.2
Meningococcal meningitis 18.9 12.23 7.44 24.57 10.67 14.76 2279 6.48 2.19
Onchocerciasis 14.8 9.7 12.7 10.2 12 11.89 1343 8.85 2.05
Lymphatic ﬁlariasis 15.38 21.36 13.71 15.82 15.21 16.29 1364 11.94 1.92
Malaria 532.6 578.1 564.5 576.8 624 575.18 45 015 12.78 1.89
TB 564.4 569.4 577.9 570.4 615.4 579.48 44 997 12.88 1.89
Schistosomiasis 24.51 26.4 20.36 18.37 24.24 22.77 1431 15.91 1.8
HIV/AIDS 1119.99 1080.93 1030.85 1102.3 1256.76 1116.16 54 446 20.5 1.69
Pneumococcal meningitis 69.2 51.38 73.67 66.1 63.35 64.74 3077 21.04 1.68
Dengue 76 85.86 101.13 112.8 81.33 91.44 2923 31.28 1.5
Leishmaniasis 34.27 44.67 40.12 41.25 44.15 40.89 774 52.83 1.28
Chagas disease 27.2 21.37 19.11 24.55 17.73 21.99 232 94.78 1.02
Total 2558 2562 2531 2649 2844 2627 180 905 – –
aAll diseases for which paired disease-speciﬁc data were available from G-FINDER and the Global Burden of Disease Study 2017.
bTotal grants to disease projects in 2017 (G-FINDER).
cMean of funding years 2013–2017, adjusted for inﬂation to 2017 US dollars.
dDALYs (Global Burden of Disease Study 2017).
eCalculated as the negative common logarithm of (DALYs [in thousands]/Funding [in US$ millions]).
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Figure 1. Research and development (R&D) funding (US$) and associated DALYs for RHD as well as 15 major tropical infectious diseases (Global
Burden of Disease Study 2017, G-FINDER public research tool 2017). Data presented on a logarithmic scale.
Figure 2. Logarithmic DNI (estimated as the negative common logarithm [−log10]) of DALYs (in thousands) divided by funding (in US$ millions) for
each disease.
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a dollar given to each of HIV/AIDs, TB and malaria. However, our
analysis is dependent on the funding and disease burden esti-
mates underlying the index. While these are the best available,
disease burden estimates for neglected diseases including RHD
are notoriously limited.10 It is likely that for RHD, both global
death and disability estimates are conservative.5 Similarly, esti-
mates of funding may be inaccurate, not least because some
smaller sources of funding may not be included in the G-FINDER
tool. Moreover, some funding may not necessarily be allocated
to a given disease, despite substantial future potential impact.
For example, funding for the development of a GAS vaccine or
work on the pathogenesis of GAS disease may have important
implications for RHD without the funding having been targeted
at RHD itself.
All diseases in this list are underfunded, especially cysticerco-
sis, soil-transmitted helminths and typhoid/paratyphoid fever,
but the huge differences seen here between RHD and other
important tropical infectious diseases is striking. We propose our
index will help make the case for further investment in RHD
research as well as become a useful tool across a variety of
tropical infectious diseases that are almost universally
underfunded.
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